STOCK TITAN
  1. Home
  2. News
  3. COR

Cencora Inc. - COR STOCK NEWS

Welcome to our dedicated news page for Cencora (Ticker: COR), a resource for investors and traders seeking the latest updates and insights on Cencora.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Cencora's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Cencora's position in the market.

News
Cencora Announces Date and Time for Second Quarter Fiscal 2024 Earnings Release
Rhea-AI Summary
Cencora, Inc. (NYSE: COR) is set to release its Second Quarter Fiscal 2024 results on May 1, 2024. The company will host a conference call featuring key executives to discuss the results. Participants can join the call via webcast or telephone, with replays available for both options.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.49%
Tags
earnings
-
News
Cencora Announces Leadership Succession Plan
Rhea-AI Summary
Cencora, Inc. (NYSE: COR) announces CEO Steven H. Collis transitioning to Executive Chair, COO Robert P. Mauch to become President and CEO effective October 1, 2024. Collis praised for 30-year career, phenomenal financial growth, global expansion, and strategic partnerships. Mauch, with extensive experience, set to continue company's pharmaceutical-centric strategy. Company reaffirms fiscal year 2024 guidance.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.1%
Tags
none
-
News
Cencora Announces Common Share Repurchase From Walgreens Boots Alliance
Rhea-AI Summary
Cencora, Inc. (NYSE: COR) has announced a $50 million share repurchase agreement with Walgreens Boots Alliance Holdings LLC, in concurrence with Walgreens Boots Alliance’s sale of Cencora shares pursuant to Rule 144 under the Securities Act of 1933. The company intends to repurchase shares at the price per share equal to the price in the Rule 144 sale, under its share repurchase program. The repurchased shares will be held in treasury.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.09%
Tags
buyback
News
Walgreens Boots Alliance Sells Shares of Cencora For $992 Million of Proceeds
Rhea-AI Summary
Walgreens Boots Alliance (WBA) has sold shares of Cencora, Inc. (COR) for $992 million, with $942 million sold pursuant to Rule 144 and a concurrent share repurchase by Cencora of approximately $50 million. The proceeds will be used for debt paydown and general corporate purposes, with no impact on the ongoing collaboration and long-term strategic partnership between the two companies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.09%
Tags
none
-
News
Cencora Closes $500 Million Senior Notes Offering
Rhea-AI Summary
Cencora, Inc. (COR) has successfully closed a public offering of $500 million aggregate principal amount of its 5.125% Senior Notes due 2034. The company filed a registration statement with the SEC and intends to use the net proceeds to redeem its 3.400% Senior Notes due May 15, 2024, with any remaining funds for general corporate purposes. The joint book-running managers for the offering were BofA Securities, Inc., Citigroup Global Markets Inc., J.P. Morgan Securities LLC, and Wells Fargo Securities, LLC.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.13%
Tags
none
-
News
Cencora Prices $500 Million 5.125% Senior Notes Due 2034
Rhea-AI Summary
Cencora, Inc. (NYSE: COR) has announced the pricing of $500 million aggregate principal amount of its 5.125% Senior Notes due 2034 in a public offering. The company plans to use the net proceeds to redeem all of its 3.400% Senior Notes due May 15, 2024, with any remaining net proceeds for general corporate purposes. The joint book-running managers for the offering are BofA Securities, Inc., Citigroup Global Markets Inc., J.P. Morgan Securities LLC, and Wells Fargo Securities, LLC. The offering is expected to close on February 7, 2024, subject to customary closing conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.34%
Tags
none
News
Cencora Reports Fiscal 2024 First Quarter Results
Rhea-AI Summary
Cencora, Inc. (NYSE: COR) reported a 15.0% increase in revenue to $72.3 billion for the first quarter of fiscal year 2024. Adjusted diluted EPS also increased by 21.0% to $3.28. The company raised its adjusted diluted EPS guidance range to $13.25 to $13.50 for fiscal 2024. U.S. Healthcare Solutions revenue grew by 15.9%, and International Healthcare Solutions revenue grew by 6.9% in the first quarter. The company's fiscal year 2024 expectations include revenue growth of 10-12% and adjusted diluted earnings per share of $13.25 to $13.50.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.51%
Tags
earnings
-
News
Cencora Announces Date and Time for First Quarter Fiscal 2024 Earnings Release
Rhea-AI Summary
Cencora, Inc. (NYSE: COR) plans to release its First Quarter Fiscal 2024 results on January 31, 2024, followed by a conference call with Chairman, President & CEO Steven H. Collis and CFO James F. Cleary. The live call will be webcast on investor.cencora.com, with replays available via telephone and webcast. Access codes provided for both live and replay calls.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.33%
Tags
earnings
-
News
Sapphiros and Cencora, formerly AmerisourceBergen Corporation, Enter into Distribution Agreement
Rhea-AI Summary
Sapphiros (COR) partners with Cencora, Inc. to distribute COVID-19 Antigen Rapid Tests and future diagnostic technologies, aiming to enhance accessibility and convenience for consumers nationwide. The agreement also includes access to upcoming Sapphiros technologies, such as multiplexed molecular diagnostics platform, rapid lateral flow tests for diseases beyond COVID-19, and the Satio™ blood collection patch in early 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.43%
Tags
none
News
Cencora Announces Common Share Repurchase From Walgreens Boots Alliance
Rhea-AI Summary
Cencora, Inc. (NYSE: COR) announces agreement to repurchase $250 million worth of common stock from Walgreens Boots Alliance Holdings LLC in concurrence with Rule 144 transactions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.38%
Tags
buyback
Stock COR logo
Cencora Inc.

NYSE:COR

COR Rankings

#258 Ranked by Market Cap
#935 Ranked by Stock Gains
#1878 Ranked by Dividends

COR Stock Data

46.63B
172.33M
13.5%
87.47%
4.07%
Drugs and Druggists' Sundries Merchant Wholesalers
Wholesale Trade
Link
US
Chesterbrook

About COR

amerisourcebergen is driving innovative partnerships with global manufacturers, providers and pharmacies to improve product access and efficiency throughout the healthcare supply chain and enhance patient care. as the leader in global sourcing and distribution, we source and distribute brand, generic, specialty, otc pharmaceuticals and other healthcare products. we increase the effectiveness and efficiency of your supply chain by ensuring products are delivered securely, consistently and cost-effectively, improving product access for pharmacies, providers and patients. our pharmacy solutions result in greater operational efficiency, cost control, growth opportunities and patient safety. our provider solutions drive operational efficiency, financial performance and improve quality of care. our manufacturer solutions maximize success at every stage of the product lifecycle. amerisourcebergen. where knowledge, reach and partnership shape healthcare delivery.